08 01 15 12 17 14

Cialis Yearly Sales

style=»" />

Cialis

Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

/> Cello Health offers a unique breadth and depth of experience, across everything from early stage product commercialisation, strategy and research.

KOL engagement: Blending accessibility with reliability KOLs and healthcare professionals these days are much more likely to be digital natives, so KOL and HCP engagement should include a blend of visibility and quality content.

Dr. Thomas Blatter has been appointed Vice President, DACH Region Dr. Thomas Blatter has been appointed VP DACH region to lead Anthill’s activities in the region, effective immediately.

Managing value: Why early asset development and commercialization is important Realising the full value of your asset – clinically and commercially – means thinking beyond the pure scientific value, even at the very early stages of development.

Quick links

Infographics

404 — Component not found

You may not be able to visit this page because of:

  1. an out-of-date bookmark/favourite
  2. a search engine that has an out-of-date listing for this site
  3. a mistyped address
  4. you have no access to this page
  5. The requested resource was not found.
  6. An error has occurred while processing your request.

Please try one of the following pages:

If difficulties persist, please contact the System Administrator of this site.

Component not found

The New York Times

A Plan to Sell Cialis, an Erectile Drug, Over the Counter

By KATIE THOMAS

May 28, 2014

Men with erectile dysfunction may be able to avoid the awkwardness of a doctor’s visit by buying the drug Cialis without a prescription, under a proposal announced Wednesday by the drug’s maker, Eli Lilly, and the French pharmaceutical company Sanofi.

Under the plan. Sanofi is buying the rights to seek approval to sell Cialis over the counter in the United States, Europe, Canada and Australia after certain patents expire. Cialis is to lose its patent protection in the United States and Europe in 2017, after which sales are expected to drop sharply as cheaper generic alternatives arrive on the market.

If approved for over-the-counter use, Cialis could gain an advantage over prescription competitors like Viagra, sold by Pfizer. But it is not clear whether the Food and Drug Administration or other regulatory bodies overseas would approve such a move: In 2008, Pfizer abandoned an effort to make Viagra available without a prescription after the European Medicines Agency raised concerns.

“Millions of men worldwide trust Cialis to treat E.D.,” or erectile dysfunction, said David A. Ricks, president of Lilly Bio-Medicines, the unit of Lilly that oversees Cialis. “We are pleased to work with Sanofi to pursue a path that could allow more men who suffer from E.D. to obtain convenient access to a safe and reliable product without a prescription.”

Although more than 45 million men have taken Cialis, according to Lilly, the drug is not without risks: Like similar treatments, it should not be taken with some heart medications because it could cause an unsafe drop in blood pressure.

A 2009 Cialis ad. The maker of Cialis, Eli Lilly, and the French firm Sanofi are in a deal to sell the drug without a prescription.

A spokeswoman for the F.D.A. said the agency would need to review what types of studies would be needed for an erectile dysfunction drug like Cialis to be sold without a prescription.

Drug companies frequently seek approval to move popular drugs to over-the-counter sales in an effort to hang onto sales when a best-selling product loses its patent protection. In 2003, AstraZeneca got approval to sell its blockbuster heartburn drug Prilosec without a prescription, and in 2012, it sold over-the-counter rights to a similar drug, Nexium, to Pfizer. The nonprescription product, Nexium 24HR, went on sale this week.

Sales of erectile dysfunction drugs have soared since Viagra was approved in 1998, but the companies that sell them have also struggled against the social stigma of male impotence. Many men, unwilling to visit a doctor for a prescription — or seeking lower prices — have turned to online marketplaces, many of which sell the drugs illegally. Last year, in an effort to recoup some of those lost sales, Pfizer began selling Viagra to consumers through its own website.

The move to make Cialis available without a prescription could be seen in a similar vein, as removing one of the hurdles — a visit to the doctor — to getting treatment.

But one urologist, Dr. Kevin L. Billups of the Johns Hopkins School of Medicine, expressed concern about moving Cialis to an over-the-counter product because, he said, erectile dysfunction can be an early warning sign for more serious conditions like diabetes and heart disease.

“Maybe you’re missing an opportunity to pick up something else,” said Dr. Billups, who is director of the school’s Men’s Health and Vitality Program.

Cialis, which was approved in the United States in 2003, brought in $2.2 billion in worldwide sales last year. Viagra, which recently lost its patent protection in several countries, brought in $1.9 billion.

We’re interested in your feedback on this page. Tell us what you think.

Related Posts:

vendita cialis in farmacia italiana
buy cheap cialis in canada
cialis serve prescrizione medica
vendita cialis generico in contrassegno
cheap cialis online europe
where can i buy legit cialis
buy cialis tablets uk
costo confezione cialis
price for cialis pills
cialis originale consegna 24 ore

Последние публикации
Материалы для утепления